On August 6, 2026, Tiziana Life Sciences Ltd announced that Chief Executive Officer Ivor Elrifi purchased 321,423 common shares on NASDAQ at $1.00 per share. This transaction increased his total holdings to 4,793,684 common shares. The company is a clinical-stage biopharmaceutical firm developing immunomodulation therapies, specifically the intranasal anti-CD3 monoclonal antibody foralumab.

On August 4, 2026, Tiziana Life Sciences Ltd announced that Chief Executive Officer Ivor Elrifi purchased 667,000 common shares on NASDAQ at $1.00 per share. This transaction increased his total holdings to 4,472,261 common shares. The company is a clinical-stage biopharmaceutical firm developing immunomodulation therapies, specifically its lead candidate intranasal foralumab.

Tiziana Life Sciences announced on July 31, 2026, that the third patient with Multiple System Atrophy (MSA) in its Phase 2 clinical trial has completed dosing with intranasal foralumab. Quantitative PET imaging results showed up to a 34% reduction in standardized uptake value and a 26% reduction in standardized uptake value ratio in brain regions affected by MSA, consistent with findings from the first two patients. These data reinforce evidence of biological activity in dampening neuroinflammation. Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company developing therapies using transformational drug delivery technologies for immunotherapy.

Executive Chairman and Founder Gabriele Cerrone, through Panetta Partners Ltd, purchased 42,357 common shares at $0.99 per share. This transaction increased his total holding to 44,814,587 common shares, representing 34.93% of the company's issued share capital. Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulation therapies.

Tiziana Life Sciences Ltd announced on June 25, 2026, that the final patient in its Phase 2a clinical trial has received the first dose of intranasal foralumab for treating non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data results are anticipated in late Q3 or early Q4 of 2026. The company intends to present these findings at the 10th joint ACTRIMS and ECTRIMS meeting in Toronto, Canada, during October 2026. Tiziana Life Sciences is a biopharmaceutical company focused on developing novel therapies.